Market Size of Global Barbiturate Drugs Industry
Study Period | 2019 - 2029 |
Base Year For Estimation | 2023 |
Forecast Data Period | 2024 - 2029 |
CAGR | 3.70 % |
Fastest Growing Market | Asia-Pacific |
Largest Market | North America |
Major Players*Disclaimer: Major Players sorted in no particular order |
Barbiturate Drugs Market Analysis
The barbiturate drug market is expected to register a CAGR of 3.7% over the forecast period, 2022-2027.
The COVID-19 pandemic has created exceptional changes in the lives of the people. For many, it has caused significant stress, anxiety, sleep disorder, and concerns about health, social isolation, employment, finances, and the challenge of balancing work and family obligations. Such a significant life event is likely to disrupt sleep and has an impact on market growth. The COVID-19 pandemic has impacted sleep. According to the American Academy of Sleep Medicine's (AASM) Sleep Prioritization Survey 2020, about a third of adults (33%) have noticed a change in their sleep quality, 30% have noticed a change in their ability to fall asleep, and 29% have noticed a change in their nightly amount of sleep. In addition, females were more likely to report that bedtimes (31%) are impacted by the COVID-19 pandemic than males (25%).
The rise in prevalence of insomnia, epilepsy, and anxiety and the increase in the geriatric population are projected to drive the global barbiturate drug market during the forecast period. For instance, according to the World Health Organization facts of 2022, epilepsy is one of the most common neurological diseases globally and affects about 50 million people worldwide. In high-income countries, about 49 per 100000 people are usually diagnosed with epilepsy each year, and in low- and middle-income countries, this figure can be as high as 139 per 100 000.
However, side effects associated with barbiturate drugs and patient expiration are expected to restrain the barbiturate drugs market over the forecast period.
Barbiturate Drugs Industry Segmentation
Barbiturates are a group of sedative-hypnotic medications used for the treatment of seizure disorder, neonatal withdrawal, insomnia, preoperative anxiety, and induction of coma for increased intracranial pressure. They are also useful for inducing anesthesia. The Barbiturate Drugs Market is segmented by Drug Type (Ultra-Short Acting Barbiturate, Short-Acting Barbiturate, Long-Acting Barbiturate, and Combination Drugs), Disease Type (Epilepsy, Insomnia, Sedation, and Other Disease Type), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Other Pharmacies), and Geography (North America, Europe, Asia-Pacific, and Rest of the World). The report offers the value (in USD million) for the above-mentioned segments.
By Drug Type | |
Ultra-Short Acting Barbiturate | |
Short-Acting Barbiturate | |
Long-Acting Barbiturate | |
Combination Drugs |
By Disease Type | |
Epilepsy | |
Insomnia | |
Sedation | |
Other Disease Type |
By Distribution Channel | |
Retail Pharmacies | |
Hospital Pharmacies | |
Other Pharmacies |
Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
Rest of the World |
Global Barbiturate Drugs Market Size Summary
The barbiturate drug market is poised for growth, driven by the increasing prevalence of conditions such as insomnia, epilepsy, and anxiety, alongside a rising geriatric population. The COVID-19 pandemic has exacerbated sleep disorders, impacting sleep quality and duration for many, which in turn has influenced market dynamics. The demand for barbiturates is expected to rise as these drugs offer potential relief for sleep-related issues and neurological conditions. However, the market faces challenges due to the side effects associated with barbiturate use and the risk of patient expiration, which may hinder growth prospects.
In the United States, the high incidence of insomnia and epilepsy, coupled with significant healthcare expenditure, is anticipated to bolster the barbiturate drug market. The presence of numerous pharmaceutical companies and the availability of these drugs further support market expansion. Key players such as Par Pharmaceutical, Akorn Operating Company LLC, and Ethypharm are currently leading the market, with strategic moves like acquisitions and establishing direct presences in new regions to enhance their market positions. Despite the fragmented nature of the market, these companies are well-positioned to capitalize on the growing demand for effective treatments.
Global Barbiturate Drugs Market Size - Table of Contents
-
1. MARKET DYNAMICS
-
1.1 Market Overview
-
1.2 Market Drivers
-
1.2.1 Rise in Prevalence of Target Diseases
-
1.2.2 Increase in Geriatric Population
-
-
1.3 Market Restraints
-
1.3.1 Side Effects Associated With Barbiturate Drugs
-
-
1.4 Porter's Five Force Analysis
-
1.4.1 Threat of New Entrants
-
1.4.2 Bargaining Power of Buyers/Consumers
-
1.4.3 Bargaining Power of Suppliers
-
1.4.4 Threat of Substitute Products
-
1.4.5 Intensity of Competitive Rivalry
-
-
-
2. MARKET SEGMENTATION (Market Size by Value - USD million)
-
2.1 By Drug Type
-
2.1.1 Ultra-Short Acting Barbiturate
-
2.1.2 Short-Acting Barbiturate
-
2.1.3 Long-Acting Barbiturate
-
2.1.4 Combination Drugs
-
-
2.2 By Disease Type
-
2.2.1 Epilepsy
-
2.2.2 Insomnia
-
2.2.3 Sedation
-
2.2.4 Other Disease Type
-
-
2.3 By Distribution Channel
-
2.3.1 Retail Pharmacies
-
2.3.2 Hospital Pharmacies
-
2.3.3 Other Pharmacies
-
-
2.4 Geography
-
2.4.1 North America
-
2.4.1.1 United States
-
2.4.1.2 Canada
-
2.4.1.3 Mexico
-
-
2.4.2 Europe
-
2.4.2.1 Germany
-
2.4.2.2 United Kingdom
-
2.4.2.3 France
-
2.4.2.4 Italy
-
2.4.2.5 Spain
-
2.4.2.6 Rest of Europe
-
-
2.4.3 Asia-Pacific
-
2.4.3.1 China
-
2.4.3.2 Japan
-
2.4.3.3 India
-
2.4.3.4 Australia
-
2.4.3.5 South Korea
-
2.4.3.6 Rest of Asia-Pacific
-
-
2.4.4 Rest of the World
-
-
Global Barbiturate Drugs Market Size FAQs
What is the current Global Barbiturate Drugs Market size?
The Global Barbiturate Drugs Market is projected to register a CAGR of 3.70% during the forecast period (2024-2029)
Who are the key players in Global Barbiturate Drugs Market?
Par Pharmaceutical , Akorn Operating Company LLC , Samarth Life Science Pvt. Ltd , Ethypharm and Abbott are the major companies operating in the Global Barbiturate Drugs Market.